Jongsook Kim Kemper

Jongsook Kim Kemper

Auto-generated profile, based on publicly available information

Jongsook Kim Kemper

Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2014 in Nature
Verified
Journal Article
Open access
PDF file
SSSunmi Seok
Sunmi Seok
TFTing Fu
Ting Fu
SCSung-E Choi
Sung-E Choi
YLYang Li
Yang Li
RZRong Zhu
Rong Zhu
JKJongsook Kim Kemper
Jongsook Kim Kemper
The FXR–CREB axis is identified as a key physiological switch that regulates autophagy during feeding/fasting cycles; in the fed state, the nuclear receptor FXR is shown to suppress autophagy in the liver by inhibiting autophagy-associated lipid breakdown triggered under fasting conditions by the transcriptional activator CREB. Autophagy — the process in which a cell digests its own components in organelles known as lysosomes — comes in various forms. A basic form involves recycling nutrients upon starvation to maintain cellular homeostasis, so it is not surprising, that the signalling mediators of nutrient sensing can modulate autophagy in the short-term. Two studies now show that starvation-induced autophagy can also be regulated through long-term transcriptional control. Jongsook Kemper and colleagues find that, in the fed state, the nuclear receptor FXR suppresses autophagy in the liver. For this, FXR seems to inhibit autophagy-associated lipid breakdown triggered under fasting conditions by the transcriptional activator CREB. David Moore and colleagues also observe FXR-mediated suppression of autophagy. In addition, they find that another nuclear receptor, PPARα, which is activated in the fasted state, triggers autophagy such that PPARα and FXR compete for binding to shared sites in the promoters of autophagic genes, with opposite transcriptional outputs. Lysosomal degradation of cytoplasmic components by autophagy is essential for cellular survival and homeostasis under nutrient-deprived conditions1,2,3,4. Acute regulation of autophagy by nutrient-sensing kinases is well defined3,5,6,7, but longer-term transcriptional regulation is relatively unknown. Here we show that the fed-state sensing nuclear receptor farnesoid X receptor (FXR)8,9 and the fasting transcriptional activator cAMP response element-binding protein (CREB)10,11 coordinately regulate the hepatic autophagy gene network. Pharmacological activation of FXR repressed many autophagy genes and inhibited autophagy even in fasted mice, and feeding-mediated inhibition of macroautophagy was attenuated in FXR-knockout mice. From mouse liver chromatin immunoprecipitation and high-throughput sequencing data12,13,14,15, FXR and CREB binding peaks were detected at 178 and 112 genes, respectively, out of 230 autophagy-related genes, and 78 genes showed shared binding, mostly in their promoter regions. CREB promoted autophagic degradation of lipids, or lipophagy16, under nutrient-deprived conditions, and FXR inhibited this response. Mechanistically, CREB upregulated autophagy genes, including Atg7, Ulk1 and Tfeb, by recruiting the coactivator CRTC2. After feeding or pharmacological activation, FXR trans-repressed these genes by disrupting the functional CREB–CRTC2 complex. This study identifies the new FXR–CREB axis as a key physiological switch regulating autophagy, resulting in sustained nutrient regulation of autophagy during feeding/fasting cycles.

8 July 2013 in Aging Cell
Verified
Journal Article
Open access
PDF file
SCSung‐E Choi
Sung‐E Choi
TFTing Fu
Ting Fu
SSSunmi Seok
Sunmi Seok
DKDong‐Hyun Kim
Dong‐Hyun Kim
EYEunkyung Yu
Eunkyung Yu
JKJongsook K. Kemper
Jongsook K. Kemper
Summary: SIRT1 is an NAD + ‐dependent deacetylase that is implicated in prevention of many age‐related diseases including metabolic disorders. As SIRT1 deacetylase activity is dependent on NAD + levels and the development of compounds that directly activate SIRT1 has been controversial, indirectly activating SIRT1 through enhancing NAD + bioavailability has received increasing attention. NAD + levels are reduced in obesity and the aged, but the underlying mechanisms remain unclear. We recently showed that hepatic microRNA‐34a (miR‐34a), which is elevated in obesity, directly targets and decreases SIRT1 expression. Here, we further show that miR‐34a reduces NAD + levels and SIRT1 activity by targeting NAMPT, the rate‐limiting enzyme for NAD + biosynthesis. A functional binding site for miR‐34a is present in the 3′ UTR of NAMPT mRNA . Hepatic overexpression of miR‐34a reduced NAMPT/NAD + levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC‐1α, SREBP‐1c, FXR, and NF‐κB, and resulted in obesity‐mimetic outcomes. The decreased NAMPT/NAD + levels were independent of miR‐34a effects on SIRT1 levels as they were also observed in SIRT1 liver‐specific knockout mice. Further, the miR‐34a‐mediated decreases were reversed by treatment with the NAD + intermediate, nicotinamide mononucleotide. Conversely, antagonism of miR‐34a in diet‐induced obese mice restored NAMPT/NAD + levels and alleviated steatosis, inflammation, and glucose intolerance. Anti‐miR‐34a‐mediated increases in NAD + levels were attenuated when NAMPT was downregulated. Our findings reveal a novel function of miR‐34a in reducing both SIRT1 expression and activity in obesity. The miR‐34a/NAMPT axis presents a potential target for treating obesity‐ and aging‐related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.

10 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSangwon Byun
Sangwon Byun
SSSunmi Seok
Sunmi Seok
YKYoung-Chae Kim
Young-Chae Kim
YZYang Zhang
Yang Zhang
PYPeter Yau
Peter Yau
JKJongsook Kim Kemper
Jongsook Kim Kemper
Autophagy is essential for cellular survival and energy homeostasis under nutrient deprivation. Despite the emerging importance of nuclear events in autophagy regulation, epigenetic control of autophagy gene transcription remains unclear. Here, we report fasting-induced Fibroblast Growth Factor-21 (FGF21) signaling activates hepatic autophagy and lipid degradation via Jumonji-D3 (JMJD3/KDM6B) histone demethylase. Upon FGF21 signaling, JMJD3 epigenetically upregulates global autophagy-network genes, including Tfeb, Atg7, Atgl, and Fgf21, through demethylation of histone H3K27-me3, resulting in autophagy-mediated lipid degradation. Mechanistically, phosphorylation of JMJD3 at Thr-1044 by FGF21 signal-activated PKA increases its nuclear localization and interaction with the nuclear receptor PPARα to transcriptionally activate autophagy. Administration of FGF21 in obese mice improves defective autophagy and hepatosteatosis in a JMJD3-dependent manner. Remarkably, in non-alcoholic fatty liver disease patients, hepatic expression of JMJD3, ATG7, LC3, and ULK1 is substantially decreased. These findings demonstrate that FGF21-JMJD3 signaling epigenetically links nutrient deprivation with hepatic autophagy and lipid degradation in mammals.

1 November 2014 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
TFTing Fu
Ting Fu
SSSunmi Seok
Sunmi Seok
SCSunge Choi
Sunge Choi
ZHZhang Huang
Zhang Huang
KSKelly Suino-Powell
Kelly Suino-Powell
JKJongsook Kim Kemper
Jongsook Kim Kemper
Brown fat generates heat through uncoupled respiration, protecting against hypothermia and obesity. Adult humans have brown fat, but the amounts and activities are substantially decreased in obesity, by unknown mechanisms. Here we show that elevated microRNA 34a (miR-34a) in obesity inhibits fat browning in part by suppressing the browning activators fibroblast growth factor 21 (FGF21) and SIRT1. Lentivirus-mediated downregulation of miR-34a in mice with diet-induced obesity reduced adiposity, improved serum profiles, increased the mitochondrial DNA copy number, and increased oxidative function in adipose tissue in both BALB/c and C57BL/6 mice. Remarkably, downregulation of miR-34a increased coexpression of the beige fat-specific marker CD137 and the browning marker UCP1 in all types of white fat, including visceral fat, and promoted additional browning in brown fat. Mechanistically, downregulation of miR-34a increased expression of the FGF21 receptor components, FGFR1 and βKL, and also that of SIRT1, resulting in FGF21/SIRT1-dependent deacetylation of PGC-1α and induction of the browning genes Ucp1, Pgc-1α, and Prdm16. Importantly, anti-miR-34a-mediated beneficial effects, including decreased adiposity, are likely from multiple tissues, since downregulation of miR-34a also improves hepatic FGF21 signaling and lipid oxidation. This study identifies miR-34a as an inhibitor of beige and brown fat formation, providing a potential target for treating obesity-related diseases.

17 September 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
TFTing Fu
Ting Fu
SCSung-E Choi
Sung-E Choi
DKDong-Hyun Kim
Dong-Hyun Kim
SSSunmi Seok
Sunmi Seok
KSKelly M. Suino-Powell
Kelly M. Suino-Powell
JKJongsook Kim Kemper
Jongsook Kim Kemper
MicroRNA-34a (miR-34a) is the most highly elevated hepatic miR in obese mice and is also substantially elevated in patients who have steatosis, but its role in obesity and metabolic dysfunction remains unclear. After a meal, FGF19 is secreted from the ileum; binds to a hepatic membrane receptor complex, FGF19 receptor 4 and coreceptor β-Klotho (βKL); and mediates postprandial responses under physiological conditions, but hepatic responses to FGF19 signaling were shown to be impaired in patients with steatosis. Here, we show an unexpected functional link between aberrantly elevated miR-34a and impaired βKL/FGF19 signaling in obesity. In vitro studies show that miR-34a down-regulates βKL by binding to the 3′ UTR of βKL mRNA. Adenoviral-mediated overexpression of miR-34a in mice decreased hepatic βKL levels, impaired FGF19-activated ERK and glycogen synthase kinase signaling, and altered expression of FGF19 metabolic target genes. Consistent with these results, βKL levels were decreased and hepatic responses to FGF19 were severely impaired in dietary obese mice that have elevated miR-34a. Remarkably, in vivo antisense inhibition of miR-34a in obese mice partially restored βKL levels and improved FGF19 target gene expression and metabolic outcomes, including decreased liver fat. Further, anti–miR-34a treatment in primary hepatocytes of obese mice restored FGF19-activated ERK and glycogen synthase kinase signaling in a βKL-dependent manner. These results indicate that aberrantly elevated miR-34a in obesity attenuates hepatic FGF19 signaling by directly targeting βKL. The miR-34a/βKL/FGF19 axis may present unique therapeutic targets for FGF19-related human diseases, including metabolic disorders and cancer.

25 November 2014 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
DKDong‐Hyun Kim
Dong‐Hyun Kim
ZXZhen Xiao
Zhen Xiao
SKSanghoon Kwon
Sanghoon Kwon
XSXiaoxiao Sun
Xiaoxiao Sun
DRDaniel Ryerson
Daniel Ryerson
JKJongsook Kim Kemper
Jongsook Kim Kemper
Acetylation of transcriptional regulators is normally dynamically regulated by nutrient status but is often persistently elevated in nutrient‐excessive obesity conditions. We investigated the functional consequences of such aberrantly elevated acetylation of the nuclear receptor FXR as a model. Proteomic studies identified K217 as the FXR acetylation site in diet‐induced obese mice. In vivo studies utilizing acetylation‐mimic and acetylation‐defective K217 mutants and gene expression profiling revealed that FXR acetylation increased proinflammatory gene expression, macrophage infiltration, and liver cytokine and triglyceride levels, impaired insulin signaling, and increased glucose intolerance. Mechanistically, acetylation of FXR blocked its interaction with the SUMO ligase PIASy and inhibited SUMO2 modification at K277, resulting in activation of inflammatory genes. SUMOylation of agonist‐activated FXR increased its interaction with NF‐κB but blocked that with RXRα, so that SUMO2‐modified FXR was selectively recruited to and trans‐repressed inflammatory genes without affecting FXR/RXRα target genes. A dysregulated acetyl/SUMO switch of FXR in obesity may serve as a general mechanism for diminished anti‐inflammatory response of other transcriptional regulators and provide potential therapeutic and diagnostic targets for obesity‐related metabolic disorders. Synopsis Acetylation levels of many transcriptional regulators are aberrantly elevated in obesity but the functional consequences are unclear. Elevated acetylation of the mouse nuclear Farnesoid X receptor (FXR) in obesity is found to inhibit its SUMOylation, constituting a molecular switch that promotes hepatic inflammation and metabolic dysfunction in vivo. Agonist‐activated FXR is SUMO2‐modified at lysine 277 by the PIASy SUMO E3 ligase. FXR SUMOylation inhibits inflammatory gene expression upon inflammatory signaling. Selective inflammatory gene trans‐repression results from increased NF‐κB and decreased RXRα interaction of SUMO2‐FXR. In obese mice, FXR acetylation at lysine 217 inhibits its SUMOylation and diminishes SUMO2‐dependent FXR anti‐inflammatory action.